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Breast cancer is the most common cancer in females worldwide, 
representing one in four cancers in women.[1,2] It is the main cause 
of cancer-related death in women in less developed regions and the 
second most common cause in more developed countries.[3] Since 
the 2008 cancer incidence estimate,[4] the incidence has increased 
worldwide by >20% and mortality by 14%, with the most rapid increase 
occurring in many developing countries.[1] According to the South 
African National Cancer Registry in 2014,[5] breast cancer accounted 
for 20.64% of all cancers[5] and ranked second as the cause of cancer 
deaths in females.[6] The current statistics are unknown.
More than 40% of patients infected with HIV will develop cancer 
during their illness.[6] Internationally, there have been very few studies 
of breast cancer in relation to HIV infection. Most of the data 
generated in the developed world were based on relatively small study 
populations of up to 20 patients and did not show any relationship 
between breast cancer and HIV infection.[7-9] The few studies in South 
Africa (SA) had substantially larger study populations and failed to 
show an increased incidence of breast cancer among HIV-infected 
patients, but they did show that HIV-infected women were younger at 
the time of presentation.[9,10] The available evidence has also suggested 
that HIV-infected cancer patients in general have a worse prognosis 
than similarly staged non-infected patients with the same cancer, and 
that they are also likely to have more advanced disease at diagnosis.[11,12]
Chemotherapy-induced neutropenia (CIN) is one of the most 
serious haematological toxicities caused by chemotherapy. [13] Its 
prevalence in HIV-infected women with breast cancer is unknown. 
Most studies have reported on CIN and HIV infection in 
haematological malignancies, and few have looked at the relationship 
between CIN and HIV infection in solid tumours.[13] Because data 
on CIN in patients with breast cancer and HIV infection are scarce, 
little is known about its incidence and management. Furthermore, 
most publications on CIN in HIV-infected patients with cancer 
have emanated from countries in the developed world. Sub-Saharan 
Africa has the highest incidence of HIV infection in the world,[14] 
and KwaZulu-Natal (KZN) is the province with the highest rate of 
infection in SA.[15]
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Background. Chemotherapy-induced neutropenia (CIN) can result in poor tolerance of chemotherapy, leading to dose reductions, delays 
in therapy schedules, morbidity and mortality. Actively identifying predisposing risk factors before treatment is of paramount importance. 
We hypothesised that chemotherapy is associated with a greater increase in CIN and its complications in HIV-infected patients than in 
those who are not infected.
Objective. To establish the incidence of CIN in HIV-infected and uninfected patients undergoing chemotherapy.
Methods. A retrospective chart review and analysis was conducted in the oncology departments at Inkosi Albert Luthuli Central Hospital 
and Addington Hospital, Durban, South Africa. The study population consisted of 65 previously untreated women of all ages with stage 
II - IV breast cancer and known HIV status treated with neoadjuvant chemotherapy from January 2012 to December 2015.
Results. HIV-infected patients formed 32.3% of the group, and 95.2% of them were on antiretroviral therapy. The mean age (standard 
deviation (SD)) of the cohort was 48.5 (13.2) years (40.6 (9.6) years for the HIV-infected group v. 52.0 (13.1) years for the uninfected group; 
p<0.001). Ninety-five neutropenia episodes were observed (rate 0.85 per 1 year of follow-up time). Following multivariate adjustment, 
patients with HIV infection were almost two times more likely to develop CIN (hazard ratio (HR) 1.76, 95% confidence interval (CI) 1.06 - 
2.92; p=0.029. A high baseline absolute neutrophil count (ANC) (HR 0.80, 95% CI 0.68 - 0.95; p=0.005) remained significantly associated 
with protection against CIN.
Conclusions. HIV-infected patients were younger than those who were not infected, and presented at a more locally advanced stage of 
disease. HIV infection was an independent predictor for CIN. HIV-infected patients had an almost two-fold increased risk of developing 
CIN and developed neutropenia at a much faster rate. A high baseline white cell count and ANC were protective against CIN.
S Afr Med J 2017;107(7):595-601. DOI:10.7196/SAMJ.2017.v107i7.12309
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We hypothesised that HIV infection predisposes patients with 
breast cancer undergoing chemotherapy to CIN and its complica-
tions.
Objective
To compare HIV-infected and uninfected patients in terms of the 
incidence and severity of complications secondary to CIN.
Methods
A retrospective chart review of all patients who underwent 
chemotherapy for breast cancer over the 4-year period 1 January 
2012 - 31 December 2015 at the oncology units at Inkosi Albert 
Luthuli Central Hospital and Addington Hospital in Durban, KZN, 
was conducted. These hospitals are tertiary referral centres for the 
coastal belt of KZN. Key data captured from the clinical notes are 
shown in Fig. 1. Primary prophylaxis was defined as the use of 
granulocyte colony-stimulating factor (G-CSF) up front from the first 
cycle of chemotherapy until the end, and secondary prophylaxis as 
use of G-CSF in response to a neutropenic complication.
Chemotherapy regimens offered in the oncology units are shown 
in Fig. 2. These regimens are considered to pose an intermediate 
(10 - 20%) risk of febrile neutropenia.[16,17] Neutropenia was defined 
according to the Common Toxicity Criteria of the National Cancer 
Institute as a disorder characterised by an absolute neutrophil count 
(ANC) of <2 × 109/L.[18,19] Neutropenia is categorised into four grades, 
depending on the ANC.
Patients
The study population consisted of previously untreated newly 
diagnosed patients of all ages with documented HIV status and 
histologically confirmed breast cancer who received neoadjuvant 
chemotherapy. The cohort consisted of women only, as men did not 
fulfil the eligibility criteria. The total number of new female patients 
diagnosed with breast cancer in the study period was 1 048, with the 
average number of new cases per year being 262. The cohort had 
stage II - IV breast cancer. Stage IV patients had oligometastases 
and received radical treatment. To minimise confounding factors, 
we excluded patients with baseline pre-existing neutropenia, those 
with a history of previous chemotherapy or a history of breast cancer 
or other prior or existing cancers, those with active infection, those 
receiving concurrent treatment with medication that predisposes to 
neutropenia, such as long-term steroids, quinidine and hydralazine, 
those who had stopped neoadjuvant chemotherapy prematurely for 
any reason other than neutropenia, and those for whom critical data 
in charts were missing (Fig. 3).
Statistical analysis
Data were analysed using Stata version 13.0 (StataCorp, USA). 
Continuous variables were summarised using means, standard 
deviations (SDs) and ranges. If data were skewed, medians and ranges 
were presented. Significant associations in contingency tables (cross-
tabulations) were assessed using Pearson’s χ2 test. If an expected cell 
count in the cross-tabulation contained <5 observations, Fisher’s 
exact test was used instead. Time-to-event (survival) analysis was 
employed to estimate the overall incidence of neutropenia and 
associated 95% confidence intervals (CIs). We constructed Kaplan-
Meier failure curves to assess differences in failure by key covariates. 
‘Failure’ was defined as failure of the patient to maintain a normal 
Fig. 1. Key parameters captured.
Fig. 2. Chemotherapy regimens used. (D1 = day 1; IVI = intravenous 
infu sion.)
Total new patients
N=1 048
Patients with known HIV 
status receiving 
neoadjuvant chemotherapy
n=71
Excluded patients
n=977
Patients excluded owing 
to baseline neutropenia
n=6
Study number at 
which statistical
signicance reached
n=65
• Adjuvant chemotherapy
• Primary endocrine therapy
• Previous breast cancer
• Unknown HIV status
• Missing data
• Declined treatment
• Surgery and radiotherapy
Fig. 3. Flow diagram of patients receiving neoadjuvant chemotherapy for 
breast cancer.
• Age
• Gender
• TNM stage (tumour, nodes, metastasis)
• American Joint Committee on Cancer stage
• Eastern Collaborative Oncology Group performance scale
• HIV status
•  CD4 cell count, HIV RNA viral load and use of antiretroviral therapy 
in HIV-infected patients
•  Endocrine receptor (oestrogen receptor, progesterone receptor) 
status
• Human epidermal growth factor receptor 2 status
•  Serum albumin level and body mass index to measure nutritional 
status
• Chemotherapy regimen employed
•  Baseline absolute neutrophil count, at administration of each 
chemotherapy cycle and in between cycles
•  White blood cell count prior to any chemotherapy, at 
administration of each chemotherapy cycle and in between cycles
• Total number of chemotherapy cycles received
• Cycle at which the first neutropenic episode occurred
• Total number of neutropenic episodes, regardless of grade
• Total number of grade 1 - 4 neutropenic episodes
• Neutropenic complications
• Number of hospital admissions
• Clinic visits for neutropenic complications
• Total number of chemotherapy deferrals due to neutropenia
•  Number of days to resume chemotherapy after a neutropenic 
episode
•  Total number of patients who did not complete chemotherapy 
regimen owing to neutropenia
• Use of granulocyte colony-stimulating factor and its indications
•  FEC: 5-FU 600 mg/m2 D1, epiadriamycin 75 mg/m2 D1 and 
cyclophosphamide 600 mg/m2 D1 IVI every 21 days × six cycles
•  FECgT (FEC-D): 5-FU 600 mg/m2 D1, epiadriamycin 75 mg/m2 D1 
and cyclophosphamide 600 mg/m2 D1 IVI every 21 days × three 
cycles, followed by docetaxel 75 mg/m2 D1 IVI every 21 days × 
three cycles
•  TC: Docetaxel 75 mg/m2 D1, cyclophosphamide 600 mg/m2 D1 IVI 
every 21 days × four cycles
•  ACgT (AC-D): Adriamycin 75 mg/m2 D1, cyclophosphamide 600 
mg/m2 D1 IVI every 21 days × four cycles, followed by docetaxel 
mg/m2 D1 IVI 3-weekly × four cycles
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neutrophil level, i.e. development of neutropenia. We further 
extended our analysis to employ bivariate and multivariate survival 
modelling (Cox proportional hazards approach) to identify covariates 
of incident neutropenia. An adjusted p-value of <0.05 was considered 
statistically significant. Only factors that were statistically significant 
on the unadjusted logistic regression analysis were entered into the 
adjusted logistic regression model.
Ethics approval
The study was approved by the Biomedical Research Ethics 
Committee of the University of KwaZulu-Natal (ref. no. BE: 094/14) 
and the Provincial Health Research Committee, KZN Department of 
Health (same reference number used).
Results
Patient characteristics
Of a total of 1 048 patients with breast cancer, 71 fulfilled the 
eligibility criteria. Subjects with pre-existing neutropenia at baseline 
(n=6) were excluded from the final analysis, yielding a final sample 
size of 65 (Fig. 3). Baseline characteristics of the cohort are shown in 
Table 1. Twenty-one patients (32.3%) were HIV-infected, of whom 
20 (95.2%) were on antiretroviral therapy (ART). The mean (SD) 
CD4 count was 435 (248) cells/µL (range 80 - 945). HIV viral loads 
were documented in only four patients. The mean age was 48 (13.2) 
years (range 24 - 80). The HIV-infected group was younger than the 
uninfected group (mean age 40 (9.6) years (range 24 - 58) v. 52 (13) 
years (range 30 - 80); p<0.001).
Sixty-one patients (93.8%) had good performance status (PS1). 
Twenty-five (38.5%) had comorbidities (p=0.072), including hyper-
tension (n=17, 68.0%), diabetes mellitus (n=11, 44.0%), osteoarthritis 
(n=6, 24.0%), dyslipidaemia (n=3, 12.0%), asthma (n=3, 12.0%) and 
ischaemic heart disease (n=2, 8.0%). Renal failure, hypothyroidism, 
cardiomyopathy, valvular heart disease and dermatomyositis 
constituted 3% of all comorbidities. Some patients had more than 
one comorbidity.
The mean (SD) baseline ANC was 4.9 (1.8) × 109/L (range 2.1 - 
8.4) and the mean baseline white cell count (WCC) 7.9 (2.2) × 109/L 
(range 3.3 - 14.9). A total of 33 patients (50.8%) experienced CIN; 
14  (66.7%) were HIV-infected and 19 (43.2%) were uninfected. 
The mean CD4 count in the neutropenic HIV-infected patients was 
378 cells/µL (range 80 - 708), compared with 509 cells/µL (range 
245 - 945) in the non-neutropenic group. There were 95 episodes 
of neutropenia, ranging from one to six episodes per patient. This 
translated into 0.85 neutropenia episodes per 1-year follow-up time 
(95% CI 0.69 - 1.04).
Table 1. Baseline characteristics of patients with breast 
cancer receiving neoadjuvant therapy (N=65)
Characteristic
Age (yr), mean (SD)* 48.5 (13.2)
HIV-positive, n (%) 21 (32.3)
ECOG performance status, n (%)
1 61 (93.9)
2 4 (6.2)
AJCC stage, n (%)
II 8 (12.3)
III 55 (84.6)
IV 2 (3.1)
ER+, n (%) 34 (52.3)
PR+, n (%) 33 (50.8)
Her 2 neu+, n (%) 14 (21.5)
CD4 count (cells/µL), mean (SD) 435.8 (248.2)
ARVs, n (%) 20 (95.2)
BMI (kg/m2), mean (SD) 28.6 (7.4)
Comorbidities, n (%) 23 (35)
Baseline ANC (× 109/L), mean (SD) 4.5 (1.7)
Baseline WCC (× 109/L), mean (SD) 7.2 (2.3)
Serum albumin (g/L), mean (SD) 42.7 (4.8)
SD = standard deviation; ECOG = Eastern Collaborative Oncology Group; AJCC = 
American Joint Committee on Cancer; ER+ = oestrogen receptor-positive; PR+ = 
progesterone receptor-positive; Her 2 neu+ = human epidermal growth factor receptor 
2-positive; ARVs = antiretrovirals; BMI = body mass index; ANC = absolute neutrophil 
count; WCC = white cell count.
*Age missing for one subject.
Table 2. Baseline characteristics of patients with breast cancer stratified by HIV status (N=65)
Characteristic HIV-negative (N=44) HIV-positive (N=21) p-value†
Age (yr), mean (SD)* 52 (13.1) 40.6 (9.6) <0.001
ECOG performance status, n (%) 1.000
1 41 (93.2) 20 (95.2)
2 3 (6.8) 1 (4.8)
AJCC stage, n (%) 0.258
II 7 (15.9) 1 (4.8)
III 35 (79.5) 20 (95.2)
IV 2 (4.5) 0 (0)
ER+, n (%) 27 (61.4) 7 (33.3) 0.034
PR+, n (%) 27 (61.4) 6 (28.6) 0.013
Her 2 neu+, n (%) 11 (25) 3 (14.3) 0.520
BMI (kg/m2), mean (SD) 29.3 (7.2) 27 (7.7) 0.242
Comorbidities, n (%) 23 (52.3) 6 (28.6) 0.072
Baseline ANC (× 109/L), mean (SD) 4.9 (1.8) 3.5 (1) 0.001
Baseline WCC (× 109/L), mean (SD) 7.9 (2.2) 5.6 (1.6) <0.001
Serum albumin (g/L), mean (SD) 43.2 (5.1) 41.5 (3.7) 0.168
SD = standard deviation; ECOG = Eastern Collaborative Oncology Group; AJCC = American Joint Committee on Cancer; ER+ = oestrogen receptor-positive; PR+ = progesterone receptor-
positive; Her 2 neu+ = human epidermal growth factor receptor 2-positive; ARVs = antiretrovirals; BMI = body mass index; ANC = absolute neutrophil count; WCC = white cell count.
*Age missing for one subject.
†Pearson’s χ2 or Fisher’s exact test for categorical characteristics and t-test for continuous explanatory characteristics.
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Table 2 compares baseline characteristics of the HIV-infected and 
non-infected patients. Compared with the uninfected group, patients 
with HIV infection had a lower body mass index (BMI) (p=0.24) 
and serum albumin level, but the latter difference was not significant 
(p=0.168).
Fifty-five patients (84.6%) presented with stage III disease; 35 HIV-
uninfected patients (79.5%) and 20 HIV-infected patients (95.2%) 
had stage III disease, suggesting that locally advanced disease was 
the predominant stage of presentation. These differences were not 
statistically significant (p=0.258). There was a significantly higher 
rate of endocrine unresponsiveness in the HIV-infected patients 
compared with those who were not infected.
Four chemotherapy regimens were used (Fig. 2). FEC was received 
by a total of 25 patients (38.5%), of whom 6 were HIV-infected. FEC-D 
was received by 32 patients (49.2%), with an equal distribution of 
HIV-infected and uninfected patients. TC was received by 6 patients 
(9.2%), of whom only 1 was HIV-infected. AC-D was received by 
2 uninfected patients (3.1%).
Neutropenia
The ratio of neutropenic episodes in HIV-infected v. uninfected 
patients was 3:1. The baseline ANC was significantly lower in HIV-
infected than in uninfected patients, and the mean WCC was also 
lower. This trend was maintained throughout chemotherapy (Fig. 4). 
Grades of neutropenia experienced by the HIV-infected v. the 
uninfected patients are shown in Table 3.
In the HIV-infected group, the lowest ANC from baseline was seen 
after the first chemotherapy infusion, namely day 1 of cycle two. The 
lowest ANC in the HIV-uninfected group was seen after the second 
chemotherapy infusion, namely day 1 of cycle three (Fig. 4). The 
mean ANCs recorded at day 1 of chemotherapy as well as in between 
chemotherapy cycles were lower in the HIV-infected patients than in 
those who were not infected (2 - 3 × 109/L v. 2 - 5 × 109/L; p<0.001) 
(Figs 4 and 5). Fig. 5 shows patients who experienced neutropenia 
and its complications in between cycles, the mean ANCs of those 
who were HIV-infected being lower than in those who were not 
(p<0.001). Mean levels declined in both groups, however, converging 
to a single level towards the end of chemotherapy. At 3.5 months 
(half way through chemotherapy), 25.0% of the overall cohort had 
developed neutropenia, while at 1 year 50.0% (median failure time) 
of the overall cohort had experienced neutropenia (Fig. 6).
The proportions of neutropenic patients in each chemotherapy 
regimen were as follows. FEC-D: 15 patients (46.9%) experienced 
neutropenia, 10 (66.7%) HIV-infected v. 5 (33.3%) uninfected; FEC: 
15 patients (60.0%) experienced neutropenia, 4 (26.7%) HIV-infected 
v. 11 (73.3%) uninfected; and TC: 3 patients (50.0%) experienced 
neutropenia, all HIV-uninfected. Neither of the 2 patients treated 
with AC-D experienced neutropenia.
Factors associated with neutropenia
At regression analysis, HIV status was a significant predictor of 
neutropenia (unadjusted hazard ratio (HR) 2.1, 95% CI 1.39 - 3.18; 
p<0.001). After adjustment for age, HIV remained a significant 
predictor of neutropenia (HR 1.76, 95% CI 1.06 - 2.92; p=0.029). 
A higher baseline ANC remained a significant factor protecting 
against the development of neutropenia (HR 0.80, 95% CI 0.68 - 
0.95; p=0.005) (Table 4). Neutropenic failure with time was greater in 
the HIV-infected group than in the uninfected group. HIV-infected 
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Fig. 4. Mean ANC by chemotherapy cycle and HIV status. (ANC = absolute 
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Table 3. Neutropenia grades in patients with chemotherapy-induced neutropenia (adapted from Cox et al.[19]) 
Grade HIV-uninfected, n (%) HIV-infected, n (%) p-value*
1 (ANC ≤1.5 - 2 × 10⁹/L) 17 (41.5) 28 (53.8)
0.616 
2 (ANC ≥1 - 1.49 × 10⁹/L) 17 (41.5) 18 (34.6)
3 (ANC ≥0.5 - 0.99 × 10⁹/L) 5 (12.3) 5 (9.6)
4 (ANC >0.5 × 10⁹/L) 2 (4.9) 1 (1.9)
ANC = absolute neutrophil count.
*The p-value represents the lack of statistically significant difference in all the four grades of neutropenia between HIV-uninfected and HIV-infected patients.
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Fig. 5. Mean ANC by follow-up visit and HIV status. (ANC = absolute 
neutro phil count; SE = standard error.)
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patients developed neutropenia at a much faster rate, i.e. 50.0% had 
already developed neutropenia at 3.5 months (half way through 
the chemotherapy schedule) compared with 30.0% of uninfected 
patients at the same point. This difference was statistically significant 
(p<0.001) (Fig. 7).
Response to neutropenia, clinical manifestations  
and sequelae
Interventions in patients who developed neutropenic complications 
included dose reduction, chemotherapy delays and G-CSF sup port. [12,20] 
Of the 33 patients who experienced frequent neutropenic episodes, 2 
(6.1%) had 25% dose reductions of their chemotherapy regimen. 
Chemotherapy delays ranging from 7 days to 5 weeks occurred in the 
neutropenic group. The median delay was 3 weeks (range 1 - 5) in the 
HIV-infected patients compared with 1 week (range 1 - 2) in those who 
were not infected. Secondary G-CSF support was given to 9 patients 
(28.1%), with 3 receiving secondary prophylactic G-CSF support from 
cycle two (filgrastim 300 µg/d subcutaneously for 3 days). All but one 
event occurred in the HIV-infected group (71.4% v. 5.3%).
There was no clear documentation of the presence or absence of 
infections and fever at the time of detection of neutropenia. Patients 
were recorded as having had lower respiratory infections (n=4), 
diarrhoea (n=2), herpes simplex infection (n=1) and herpes zoster 
infection (n=1).
One episode of febrile neutropenia in one patient occurred after 
the first cycle of chemotherapy. The patient had HIV infection, with 
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Fig. 6. Neutropenia (neutrophil failure) progression over time in the whole 
group of patients receiving chemotherapy. (CI = confidence interval.)
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Fig. 7. Neutropenia (neutrophil failure) progression over time in HIV-
positive and negative patients receiving chemotherapy.
Table 4. Cox regression analysis of factors associated with neutropenia*
Characteristic
Number of 
neutropenia events 
per annum Unadjusted HR (95% CI) p-value Adjusted HR (95% CI) p-value
HIV status
 + 41/68.6 1 (ref)
 – 52/41 2.1 (1.39 - 3.18) <0.001 1.76 (1.06 - 2.92) 0.029
Age 93/109.7 0.97 (0.95 - 0.99) 0.002 0.98 (0.96 - 1.00) 0.062
ECOG performance status
1 89/103.4 1 (ref)
2 4/6.2 0.66 (0.24 - 1.8) 0.414
AJCC stage
II 6/10.4 1 (ref)
III 86/96.9 1.61 (0.7 - 3.71) 0.258
IV 1/2.4 0.69 (0.08 - 5.76) 0.734
ER+ 54/68.7 0.92 (0.61 - 1.4) 0.709
PR+ 46/66.8 0.67 (0.45 - 1.02) 0.062
Her 2 neu+ 13/23.4 0.59 (0.33 - 1.07) 0.08
Comorbidities 29/38.8 0.76 (0.49 - 1.19) 0.229
BMI (kg/m2) 93/109.7 1 (0.98 - 1.02) 0.952
Baseline ANC (× 109/L) 93/109.7 0.81 (0.71 - 0.93) 0.003 0.80 (0.68 - 0.94) 0.005
Baseline WCC (× 109/L) 93/109.7 0.88 (0.81 - 0.96) 0.006 Excluded due to collinearity with 
baseline ANC
Serum albumin (g/dL) 93/109.7 0.97 (0.92 - 1.03) 0.301
HR = hazard ratio; CI = confidence interval; + = positive; – = negative; ECOG = Eastern Collaborative Oncology Group; AJCC = American Joint Committee on Cancer; ER+ = oestrogen 
receptor-positive; PR+ = progesterone receptor-positive; Her 2 neu+ = human epidermal growth factor receptor 2-positive; BMI = body mass index; ANC = absolute neutrophil count;  
WCC = white cell count.
*Only factors that were statistically significant on the unadjusted logistic regression analysis were entered into the adjusted logistic regression model.
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a baseline CD4 count of 175 cells/µL and a viral load of 822 940 
copies/L, and was not on ART. Her septic screen was negative and she 
was given intravenous antibiotics and prophylactic G-CSF support 
(filgrastim 300 µg/d subcutaneously for 3 days), and was in hospital 
for 9 days. There were no further neutropenic episodes in subsequent 
cycles, as she received secondary prophylaxis.
One patient with neutropenia did not complete her chemotherapy 
schedule, which was aborted after two cycles owing to inability to 
achieve normal ANC levels after the first dose of chemotherapy. She 
had six recorded episodes of grade 2 - 3 neutropenia over a period 
of 14 weeks during her chemotherapy schedule. The complication 
experienced was a respiratory infection, which was managed on 
an outpatient basis with oral antibiotics. She was 50 years old, with 
HIV infection and stage III breast cancer. She had a CD4 count of 
477 cells/µL and a viral load of 23 296 copies/L, but was not on ART. 
She was commenced on tamoxifen 20 mg/d, and the tumour was 
deemed resectable 7 months later. None of the study patients died.
Discussion
Neutropenia can result in poor tolerance to chemotherapy, leading to 
dose reductions, delays in chemotherapy administration, morbidity 
and mortality, and can ultimately influence treatment outcomes.[13,18] 
Active identification of predisposing risk factors prior to commencing 
chemotherapy is essential. In this study, HIV infection was shown to 
be an independent predictor of CIN. Decreased immunity due to 
active infection, myelosuppressive drugs and comorbidities have been 
reported as risk factors for developing CIN,[18-22] but HIV infection as 
an independent predictor of CIN in patients with solid tumours has 
not been reported. Neutropenia is a significant independent risk 
factor for bacteraemia in HIV-positive patients. It has been reported 
to occur in 35 - 75% of patients with AIDS.[23] CIN also occurred at 
a much faster rate in patients with HIV infection in our cohort. We 
postulate that this is because HIV-negative patients have an immune 
advantage over infected patients. HIV infection causes neutrophil 
dysfunction in a number of ways, including impaired chemotaxis 
and phagocytosis, an accelerated number of apoptotic neutrophils, 
expression of cellular adhesion molecules at the surface of the 
neutrophils, and production of toxic oxygen species.[23] Neutropenia 
and neutrophil dysfunction associated with HIV infection are 
partly mediated by abnormal regulation of cytokines.[23] In response 
to neutropenia, cytokines are released to increase the production 
of neutrophils. In the presence of HIV infection this is impaired 
somewhat, resulting in the neutropenic patient recovering much 
more slowly, with increased episodes and a more severe degree of 
neutropenia than in an HIV-uninfected neutropenic patient. HIV-
infected patients may have other compounding morbidities such as 
opportunistic infections and manifestations of AIDS, and some may 
already have a baseline neutropenia due to their HIV infection before 
they start chemotherapy.[23] Furthermore, malignancy in itself can 
cause myelosuppression.[23,24] These factors are thought to contribute 
to HIV-infected patients’ higher risk of developing neutropenia.
We also showed that a higher baseline ANC and WCC were 
associated with 18% protection against CIN. Baseline ANC was 
also established as a means of predicting the development of CIN 
in a study by Jenkins and Freeman.[25] Retrospective studies have 
demonstrated the predictive value of pre-treatment WCCs[24-27] and 
first-cycle nadir WCCs for predicting neutropenic complications 
in later cycles.[26] The baseline ANC is indicative of bone marrow 
reserve. Nadir ANCs and WCCs were much lower in the HIV-
infected patients in our study compared with the HIV-uninfected 
patients, and this trend seemed to be maintained throughout the 
chemotherapy cycles. Mean ANC levels in the HIV-infected patients 
who experienced neutropenia were initially much lower than those 
in uninfected patients, but in the last few visits towards the end of 
chemotherapy the mean ANC levels of the two groups converged as 
the mean ANC of the HIV-uninfected group continued to decline 
at a relatively higher rate. It is not known why this occurred, but it 
is postulated that the initial advantage of a higher mean ANC in the 
uninfected patients was lost towards the end of treatment as their 
bone marrow haematopoietic reserve decreased.
Sequential chemotherapy appears to increase the likelihood of 
an HIV-infected patient experiencing neutropenia. More HIV-
infected patients in our FEC-D group than on other regimens 
developed neutropenia. The group receiving FEC alone had more 
HIV-uninfected patients who experienced neutropenia. The reason 
for this is unknown.
ART did not prevent patients with HIV infection from experiencing 
neutropenia, but it did protect them from developing higher grades 
of neutropenia and more severe complications. The two neutropenic 
patients who were not on ART had CIN throughout chemotherapy, 
with higher grades resulting in severe complications and the need for 
G-CSF support and even to stop chemotherapy.
This study has shown that HIV-infected patients with breast 
cancer present at a significantly younger age than their uninfected 
counterparts. Cancers do occur at an earlier age in both women 
and men with HIV infection than in non-infected individuals.[28] SA 
studies on breast cancer have also found that HIV-infected patients 
presented at a much younger age and at a more advanced stage than 
those who were uninfected.[9,10] In our study, HIV-infected patients 
tended to present with more locally advanced disease, although this 
was not statistically significant. There are studies that support our 
finding of HIV-infected cancer patients being likely to have more 
advanced disease at diagnosis than similarly staged non-infected 
patients, and to have a poorer prognosis.[7,11,12,28] This could be due 
to the direct and indirect effects of the HIV virus on cancer biology. 
An indirect consequence of HIV infection is long-term immune 
suppression and alterations.[28] The more direct effects of the HIV 
virus include HIV tat protein transactivation of cellular genes or 
proto-oncogenes. Numerous HIV genes have been reported to 
inhibit tumour suppressor genes such as p53.[28] Impairment of the 
immune system and the ability of cancer cells to evade the immune 
system has been established as a hallmark in cancer biology.[29] Since 
the introduction of ART, reduction in other causes of death and 
better supportive care, patients with HIV have been living longer, 
and it is unknown whether the incidence of breast cancer will 
increase. [28] Even though ART has had a massive impact on cancer 
in the HIV setting, infected patients are still at higher cancer risk 
than the general population. An explanation of the increased risk is 
that, despite improved immune function on ART, cancer immune 
surveillance is still inadequate in patients with HIV.[30] Furthermore, 
HIV-infected women are less likely than those who are uninfected 
to undergo routine screening mammography, which may ultimately 
play a role in later diagnosis and more advanced presentation of 
breast cancer.[11,31] A high proportion of HIV-infected patients are 
young, and routine screening methods and education have largely 
targeted older women. Whether HIV infection alters the presentation 
or outcome of breast cancer is unknown,[9] as there have not yet been 
any large prospective cohort studies.[8,11]
Reduction of a patient’s chemotherapy dose in response to 
neutropenia may lead to improvement of the neutropenia. However, 
like many other drugs, chemotherapeutic drugs have a dose-response 
relationship.[13,22] It has been demonstrated that decreasing the dose in 
patients with breast cancer may decrease efficacy.[22] Dose reduction 
is therefore not an ideal option, and growth factor support should be 
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considered as an alternative.[21,22] Evidence suggests that prevention 
of neutropenia with G-CSF is more beneficial than treatment of 
established neutropenia.[21] Most neutropenic episodes occur in 
the early cycles of chemotherapy, and its early development has an 
influence on tolerance of subsequent cycles. Early use of G-CSF 
affects the risk of neutropenia in later cycles, perhaps owing to the 
priming effect on myeloid precursors.[13,32]
An unexpected finding was that increasing age was marginally 
associated with a protective effect following multivariate adjustment. 
Age in this instance may be a confounding factor, as HIV-infected 
patients tend to be relatively young and CIN was more common in 
HIV-infected patients. Other studies do not support this observation, 
and have found older age to be a risk factor for CIN.[24]
Eastern Cooperative Oncology Group  (ECOG)  performance 
status, TNM stage, BMI, serum albumin level and the presence of 
co mor bidities had no influence on CIN in this series. This is not in 
keeping with the findings of other studies in which these factors have 
been shown to influence CIN, resulting in their being incorporated 
into oncology guidelines.[16,17,21]
Recommendations
We are in agreement with Schouten[22] that primary G-CSF prophy-
laxis should be considered in patients with HIV infection who 
receive chemotherapy for breast cancer. In endocrine-responsive 
HIV-infected patients, who have a >20% risk of developing 
neutropenia, we suggest primary endocrine therapy as an alternative 
to chemotherapy in the neoadjuvant setting. Endocrine therapy has 
been used successfully in this setting[33-36] owing to its favourable side-
effect profile.[37] Routine HIV testing of all patients diagnosed with 
cancer should become a standard. Those who are infected should 
have their CD4 cell count and HIV viral load measured. Evidence 
suggests that it is beneficial to start these patients on ART prior to any 
oncological treatment.[38,39] We suggest that criteria for chemotherapy 
parameters (ANC and WCC) in HIV-infected patients should be 
modified to account for their lower ANC trends from baseline to 
completion, as this seems to be the norm for this group.
Study limitations
This was a retrospective study, and it relied completely on previously 
recorded data. A number of factors negatively affected the study, 
including incomplete documentation, test results and recording of 
HIV status. A larger prospective study is likely to strengthen the 
findings of this study.
Conclusions
This study has established HIV infection as an independent predictor 
of CIN, with HIV-infected patients being two times more likely to 
experience CIN and having a faster development rate than those 
who are uninfected. Higher baseline WCCs and ANCs are protective 
against developing CIN, and vice versa. HIV-infected patients 
should be regarded as at high risk of developing CIN, and primary 
prophylaxis should therefore be considered.
Acknowledgements. None.
Author contributions. Conception and design: SN; collection of data and 
assembly: SN; data analysis and interpretation: SN, BS; manuscript writing 
and editing: all authors; final approval of manuscript: all authors; critical 
revision for intellectual content: TEM.
Funding.  This research did not receive any specific grant from funding 
agencies in the public, commercial or not-for-profit sectors.
Conflicts of interest. None.
1. Global cancer burden rises to 14.1 million new cases in 2012: Marked increase in breast cancers must 
be addressed. Cancer IAFRO, 2013. http://www.iarc.fr/en/media-center/pr/2013/pdfs/pr233_E.pdf 
(accessed 19 February 2016).
2. Ferlay J, Soerjomataram I, Ervik M, et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality 
Worldwide: IARC CancerBase No. 11. Lyon, France: International Agency for Research on Cancer, 2013. 
http://globocan.iarc.fr (accessed 23 October 2016).
3. Vorobiof DA, Sitas F, Vorobiof G. Breast cancer incidence in South Africa. J Clin Oncol 2001;19(Suppl 
18):125-127.
4. Ferlay J, Shin H-R, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 
2008: GLOBOCAN 2008. Int J Cancer 2010;127(12):2893-2917. https://doi.org/10.1002/ijc.25516
5. Sitas F. Histologically diagnosed cancers in South Africa, 1988. S Afr Med J 1994;84(6):344-348.
6. Hurley J, Franco S, Gomez-Fernandez C, et al. Breast cancer and human immunodeficiency virus: A report 
of 20 cases. Clin Breast Cancer 2001;2(3):215-220. https://doi.org/10.1016/S1526-8209(11)70416-5
7. Patel P, Hanson DL, Sullivan PS, et al. Incidence of types of cancer among HIV-infected persons compared 
with the general population in the United States, 1992 - 2003. Ann Intern Med 2008;148(10):728-736. 
http://doi.org/10.7326/0003-4819-148-10-200805200-00005
8. Palan M, Shousha S, Stebbing J. Breast cancer in the setting of HIV. Pathol Res Int 2011;2011:1-4. http://
dx.doi.org/10.4061/2011/925712
9. Cubasch H, Joffe M, Hanisch R, et al. Breast cancer characteristics and HIV among 1,092 women in Soweto, 
South Africa. Breast Cancer Res Treat 2013;140(1):177-186. https://doi.org/10.1007/s10549-013-2606-y
10. Langenhoven L, Barnardt P, Neugut AI, Jacobson JS. Phenotype and treatment of breast cancer in HIV-
positive and-negative women in Cape Town, South Africa. J Glob Oncol 2016;2(5):284-291. https://doi.
org/10.1200/JGO.2015.002451
11. De Andrade ACV, Luz PM, Veloso VG, et al. Breast cancer in a cohort of human immunodeficiency virus 
(HIV)-infected women from Rio de Janeiro, Brazil: A case series report and an incidence rate estimate. 
Braz J Infect Dis 2011;15(4). http://dx.doi.org/10.1590/S1413-86702011000400016
12. Voutsadakis IA, Silverman LR. Breast cancer in HIV-positive women: A report of four cases and review of 
literature. Cancer Invest 2002;20(4):452-457. http://dx.doi.org/10.1081/CNV-120002144
13. Crawford J, Dale DC, Lyman GH. Chemotherapy‐induced neutropenia: Risks, consequences and new 
directions for its management. Cancer 2004;100(2):228-237. https://doi.org/10.1002/cncr.20218
14. UNAIDS. Reports on the global epidemic 2008. http//www.unaids.org/site/default/file/media_asset/
jc1510_2008globalreport_en_0.pdf (accessed 29 May 2016).
15. Shisana O, Labadarios D, Simbayi L, et al. South African National HIV Prevalence, Incidence and 
Behaviour Survey, 2012. Cape Town: HSRC Press, 2014.
16. Crawford J, Althaus B, Armitage JO, et al. Myeloid growth factors. Clinical practice guidelines in 
oncology. J Natl Compr Canc Netw 2007;5(2):188-202. http://dx.doi.org/10.6004/jnccn.2007.0019.
17. Aapro MS, Cameron DA, Pettengell R, et al. EORTC guidelines for the use of granulocyte-colony 
stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients 
with lymphomas and solid tumours. Eur J Cancer 2006;42(15):2433-2453. https://doi.org/10.1016/j.
ejca.2006.05.002
18. Crawford J, Dale DC, Lyman GH. Chemotherapy-induced neutropenia: Risks, consequences, and new 
directions for its management. Cancer 2004;100(2):228-237. https://doi.org/10.1002/cncr.11882
19. Cox JD, Stetz J, Pajak TF. Toxicity criteria of the radiation therapy oncology group (RTOG) and the 
European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys 
1995;31(5):1341-1346. https://doi.org/10.1016/0360-3016(95)00060-C
20. Chen K, Zhang X, Deng H, et al. Clinical predictive models for chemotherapy-induced neutropenia 
in breast cancer patient: A validation study. PLoS One 9(6):e96413. https://doi.org/10.1371/journal.
pone.0096413
21. Smith TJ, Khatcheressian J, Lyman GH, et al. 2006 update of recommendations for the use of white blood 
cell growth factors: An evidence-based clinical practice guideline. J Clin Oncol 2006;24(19):3187-3205. 
https://doi.org/10.1200/JCO.2006.06.4451
22. Schouten H. Neutropenia management. Ann Oncol 2006;17(Suppl 10):x85-x89. https://doi.org/10.1093/
annonc/mdl243
23. Kuritzkes DR. Neutropenia, neutrophil dysfunction, and bacterial infection in patients with human 
immunodeficiency virus disease: The role of granulocyte colony-stimulating factor. Clin Infect Dis 
2000;30(2):256-260. https://doi.org/10.1086/313642
24. Lyman GH, Lyman CH, Agboola O, for the ANC Study Group. Risk models for predicting chemotherapy-
induced neutropenia. Oncologist 2005;10(6):427-437. https://doi.org/10.1634/theoncologist.10-6-427
25. Jenkins P, Freeman S. Pre-treatment haematological laboratory values predict for excessive 
myelosuppression in patients receiving adjuvant FEC chemotherapy for breast cancer. Ann Oncol 
2009;20(1):34-40. https://doi.org/10.1093/annonc/mdn560
26. Silber JH, Fridman M, DiPaola RS, Erder MH, Pauly MV, Fox KR. First-cycle blood counts and 
subsequent neutropenia, dose reduction, or delay in early-stage breast cancer therapy. J Clin Oncol 
1998;16(7):2392-2400.
27. López-Pousa A, Rifà J, Casas de Tejerina A, et al. Risk assessment model for first-cycle chemotherapy-
induced neutropenia in patients with solid tumours. Eur J Cancer Care 2010;19(5):648-655. https://doi.
org/10.1111/j.1365-2354.2009.01121.x
28. Mitsuyasu R. Non-AIDS-defining malignancies in HIV. Top HIV Med 2008;16(4):117-121.
29. Hanahan D, Weinberg RA. Hallmarks of cancer: The next generation. Cell 2011;144(5):646-674. https://
doi.org/10.1016/j.cell.2011.02.013
30. Bedimo R, Chen RY, Accortt NA, et al. Trends in AIDS-defining and non-AIDS-defining malignancies 
among HIV-infected patients: 1989 - 2002. Clin Infect Dis 2004;39(9):1380-1384. https://doi.
org/10.1086/424883
31. Krishnan A, Levine AM. Malignancies in women with HIV infection. Womens Health 2008;4(4):357-368.
32. Crawford J. Pegfilgrastim for the prevention of chemotherapy-induced neutropenic complications, with 
dosing once per chemotherapy cycle. Todays Ther Trends 2002;S20(4):393-418.
33. Cataliotti L, Buzdar AU, Noguchi S, et al. Comparison of anastrozole versus tamoxifen as preoperative 
therapy in postmenopausal women with hormone receptor‐positive breast cancer. Cancer 
2006;106(10):2095-2103. https://doi.org/10.1002/cncr.21872
34. Masuda N, Sagara Y, Kinoshita T, et al. Neoadjuvant anastrozole versus tamoxifen in patients receiving 
goserelin for premenopausal breast cancer (STAGE): A double-blind, randomised phase 3 trial. Lancet 
Oncol 2012;13(4):345-352. https://doi.org/10.1016/51470-2045(11)70373-4
35. Smith IE, Dowsett M, Ebbs SR, et al. Neoadjuvant treatment of postmenopausal breast cancer with 
anastrozole, tamoxifen, or both in combination: The Immediate Preoperative Anastrozole, Tamoxifen, 
or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial. J Clin Oncol 
2005;23(22):5108-5116. https://doi.org/10.1200/JCO.2005.04.005
36. Eiermann W, Paepke S, Appfelstaedt J, et al. Preoperative treatment of postmenopausal breast cancer 
patients with letrozole: A randomized double-blind multicenter study. Ann Oncol 2001;12(11):1527-
1532. https://doi.org/10.1023/A:1013128213451
37. Charehbili A, Fontein D, Kroep J, et al. Neoadjuvant hormonal therapy for endocrine sensitive 
breast cancer: A systematic review. Cancer Treat Rev 2014;40(1):86-92. https://doi.org/10.1016/j.
ctrv.2013.06.001
38. Kaplan JE, Benson C, Holmes KK, et al. Guidelines for prevention and treatment of opportunistic 
infections in HIV-infected adults and adolescents. MMWR Recomm Rep 2009;58(RR-4):1-207.
39. Torres HA, Mulanovich V. Management of HIV infection in patients with cancer receiving chemotherapy. 
Clin Infect Dis 2014;59(1):106-114. https://doi.org/http://doi.org/10.1093/cid/ciu174
Accepted 6 March 2017.
